Abbott Laboratories Management

Management criteria checks 3/4

Abbott Laboratories' CEO is Robert Ford, appointed in Oct 2018, has a tenure of 5.5 years. total yearly compensation is $23.27M, comprised of 6.4% salary and 93.6% bonuses, including company stock and options. directly owns 0.024% of the company’s shares, worth €41.97M. The average tenure of the management team and the board of directors is 5 years and 5.2 years respectively.

Key information

Robert Ford

Chief executive officer

US$23.3m

Total compensation

CEO salary percentage	6.4%
CEO tenure	5.5yrs
CEO ownership	0.02%
Management average tenure	5yrs
Board average tenure	5.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Robert Ford's remuneration changed compared to Abbott Laboratories's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$23m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$5b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$22m	US$2m	US$7b
Sep 30 2022	n/a	n/a	US$8b
Jun 30 2022	n/a	n/a	US$9b
Mar 31 2022	n/a	n/a	US$8b
Dec 31 2021	US$25m	US$1m	US$7b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$6b
Dec 31 2020	US$20m	US$1m	US$4b
Sep 30 2020	n/a	n/a	US$3b
Jun 30 2020	n/a	n/a	US$3b
Mar 31 2020	n/a	n/a	US$4b
Dec 31 2019	US$12m	US$1m	US$4b
Sep 30 2019	n/a	n/a	US$3b
Jun 30 2019	n/a	n/a	US$3b
Mar 31 2019	n/a	n/a	US$3b
Dec 31 2018	US$8m	US$784k	US$2b
Sep 30 2018	n/a	n/a	US$802m
Jun 30 2018	n/a	n/a	US$812m
Mar 31 2018	n/a	n/a	US$365m
Dec 31 2017	US$5m	US$675k	US$344m

Compensation vs Market: Robert's total compensation ($USD23.27M) is above average for companies of similar size in the German market ($USD5.66M).

Compensation vs Earnings: Robert's compensation has been consistent with company performance over the past year.

CEO

Robert Ford (49 yo)

5.5yrs

Tenure

US$23,268,171

Compensation

Mr. Robert B. Ford has been the Chief Executive Officer of Abbott Laboratories since March 31, 2020 and also serves as its Chairman of the Board since December 10, 2021. He has been President at Abbott Lab...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Robert Ford	Chairman of the Board	5.5yrs	US$23.27m	0.024% $ 42.0m
Philip Boudreau	CFO & Senior VP of Finance	less than a year	US$3.32m	0.0023% $ 4.0m
Hubert Allen	Executive VP	11.3yrs	US$7.42m	0.011% $ 18.6m
Robert Funck	Executive Vice President of Finance	less than a year	US$8.99m	0.016% $ 27.2m
Daniel Salvadori	Executive VP and Group President of Established Pharmaceuticals & Nutritional Products	9.6yrs	US$5.93m	0.0072% $ 12.6m
Lisa Earnhardt	Executive VP & Group President of Medical Devices	5.3yrs	US$5.50m	0.0049% $ 8.5m
Sabina Ewing	Senior VP of Business & Technology Services and Chief Information Officer	less than a year	no data	no data
Erica Battaglia	VP and Chief Ethics & Compliance Officer	no data	no data	no data
Melissa Brotz	Vice President of Public Affairs & Corporate Marketing	no data	no data	no data
Christopher Scoggins	Senior Vice President of Commercial Operations	1.3yrs	no data	no data
Mary Moreland	Executive Vice President of Human Resources	4.7yrs	no data	0.0059% $ 10.3m
Jared Watkin	Executive Vice President of Diabetes Care	8.8yrs	no data	0.0042% $ 7.2m

5.0yrs

Average Tenure

53yo

Average Age

Experienced Management: ABL's management team is considered experienced (5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Robert Ford	Chairman of the Board	4.4yrs	US$23.27m	0.024% $ 42.0m
Daniel Starks	Independent Director	7.2yrs	US$349.29k	0.39% $ 674.5m
John Stratton	Independent Director	7.3yrs	US$316.95k	0.00020% $ 348.8k
Nancy McKinstry	Lead Independent Director	12.3yrs	US$335.95k	0.00027% $ 470.9k
Michael Roman	Independent Director	3yrs	US$337.96k	0% $ 0
Robert Alpern	Independent Director	15.5yrs	US$441.44k	0% $ 0
Michael O'Grady	Independent Director	less than a year	US$283.96k	0% $ 0
Michelle Kumbier	Independent Director	5.8yrs	US$316.95k	0.00018% $ 314.0k
Sally Blount	Independent Director	12.3yrs	US$340.70k	0.00015% $ 261.6k
Claire Babineaux-Fontenot	Independent Director	1.6yrs	US$31.50k	0% $ 0
Darren McDew	Independent Director	4.6yrs	US$331.19k	0% $ 0
Patricia Gonzalez	Independent Director	2.7yrs	US$356.96k	0% $ 0

5.2yrs

Average Tenure

61yo

Average Age

Experienced Board: ABL's board of directors are considered experienced (5.2 years average tenure).

Abbott Laboratories Management

Management criteria checks 3/4

Key information

Recent management updates

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Independent Director recently sold €4.5m worth of stock

Independent Director recently sold €5.2m worth of stock

Abbott Laboratories Announces Management Changes, Effective September 1, 2023

Abbott Laboratories Announces Executive Changes

Recent updates

First quarter 2024 earnings released: EPS: US$0.70 (vs US$0.75 in 1Q 2023)

Abbott Laboratories Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Upcoming dividend of US$0.55 per share

Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside

Abbott Receives FDA Approval for Triclip™, First-Of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve

Abbott Laboratories to Report Q1, 2024 Results on Apr 17, 2024

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Abbott Announces Real-World Data Show Freestyle Libre Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Fourth quarter dividend of US$0.55 announced

Abbott Declares Quarterly Cash Dividend, Payable on May 15, 2024

FDA Advisory Committee Votes in Favor of Abbott's First-Of-Its-Kind TriClip System to Treat People with a Leaky Tricuspid Heart Valve

Now 21% overvalued after recent price rise

Abbott Laboratories Announces the Launch of Its New PROTALITY Brand

Abbott Launches Smallest Rechargeable System with Remote Programming Capabilities to Treat Movement Disorders

Full year 2023 earnings released: EPS: US$3.27 (vs US$3.94 in FY 2022)

Abbott Laboratories Provides Earnings Guidance for the Full Year 2024

Abbott Laboratories Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

Abbott Laboratories Announces Quarterly Dividend Payable on Feb. 15, 2024

Abbott Announces New Late-Breaking Data That Show Advanced Heart Failure Patients Living with its HeartMate 3 Heart Pump

Abbott's Food as Medicine Program Showed Clinically Significant Improvements in Managing Diabetes

Now 21% undervalued after recent price drop

Abbott Laboratories Receives FDA Approval for HPV Test to Run on Alinity m, Offering Primary HPV Screening and Assessment of High-Risk Cancer-Causing Types of HPV

Independent Director recently sold €4.5m worth of stock

Abbott Announces Late-Breaking Data from the LIFE-BTK Clinical Trial Evaluating the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System

Late-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves

Third quarter 2023 earnings released: EPS: US$0.82 (vs US$0.81 in 3Q 2022)

Abbott Laboratories Provides Earnings Guidance for the Full Year 2023

Upcoming dividend of US$0.51 per share at 2.1% yield

Abbott Laboratories to Report Q3, 2023 Results on Oct 18, 2023

Abbott Laboratories (NYSE:ABT) acquired Bigfoot Biomedical, Inc..

Abbott Declares Quarterly Dividend, Payable on November 15, 2023

Canadian First - Abbott's Tactiflex™ Ablation Catheter Used to Treat Afib

Abbott Laboratories (NYSE:ABT) entered into definitive agreement to acquire Bigfoot Biomedical, Inc.

Independent Director recently sold €5.2m worth of stock

Abbott Laboratories Provides Earnings Guidance for the Full Year 2023

New minor risk - Profit margin trend

Second quarter 2023 earnings released: EPS: US$0.79 (vs US$1.15 in 2Q 2022)

Upcoming dividend of US$0.51 per share at 1.9% yield

Abbott Laboratories to Report Q2, 2023 Results on Jul 20, 2023

Abbott Laboratories Announces Management Changes, Effective September 1, 2023

Abbott Declares Quarterly Common Cash Dividend, Payable on August 15, 2023

Abbott Receives FDA Approval for Tactiflex Ablation Catheter for Treatment of Abnormal Heart Rhythm

Abbott Receives FDA Clearance for Assert-IQ™? Insertable Cardiac Monitor to Help Doctors Monitor People's Heart Rhythms Long-Term

First quarter 2023 earnings released: EPS: US$0.75 (vs US$1.38 in 1Q 2022)

Now 20% undervalued after recent price drop

Upcoming dividend of US$0.51 per share at 2.0% yield

Abbott Declares Quarterly Dividend, Payable on May 15, 2023

Abbott Laboratories (NYSE:ABT) entered into a definitive agreement to acquire Cardiovascular Systems, Inc. (NasdaqGS:CSII) for approximately $880 million.

Abbott Laboratories Announces the U.S. Food and Drug Administration Approves Its Proclaim™ XR

Full year 2022 earnings released: EPS: US$3.93 (vs US$3.97 in FY 2021)

Abbott Laboratories Provides Earnings Guidance for the Full-Year 2023

Abbott Receives FDA Approval for Navitor™, a Next-Generation TAVI System Designed to Treat Aortic Stenosis

Abbott and Blood Centers of America Launch First-of-its-Kind Mixed Reality Experience for Use During Blood Donation

Abbott Laboratories to Report Q4, 2022 Results on Jan 25, 2023

Upcoming dividend of US$0.51 per share

Abbott's FreeStyle Libre® 3 Integrated with Automated Insulin Delivery System mylife™ Loop in Germany

Abbott Laboratories Launches the Smallest Implantable, Rechargeable Spinal Cord Stimulation System for Chronic Pain

Abbott Increases Quarterly Dividend, Payable Feb. 15, 2023

Abbott Launches Panbio HIV Self Test at Retail, Increasing Access to Faster, Reliable and Discrete Testing at Home

Third quarter 2022 earnings released: EPS: US$0.81 (vs US$1.18 in 3Q 2021)

Abbott's Freestyle Libre(R) 2 System Has Positive Impacts on Glucose Levels and Quality of Life

Upcoming dividend of US$0.47 per share

Abbott Laboratories to Report Q3, 2022 Results on Oct 19, 2022

Late-Breaking Data Show Breadth of Abbott's Minimally Invasive Structural Heart Technologies

Abbott Declares Quarterly Common Dividend, Payable November 15, 2022

Abbott Announces Three-Year Data on World's Smallest Heart Device Show Benefits of Fixing Holes in Newborn Hearts Without Surgery

Rosen Law Firm Files Class Action Lawsuit on Behalf of Purchasers of the Securities of Abbott Laboratories

The Portnoy Law Firm Files A Class Action Lawsuit Filed on Behalf of Investors Against Abbott Laboratories

New Data Show Abbott's HeartMate 3™ Heart Pump Extends Life Beyond Five Years for Advanced Heart Failure Patients

U.S. Food and Drug Administration Approves Abbott's New Spinal Cord Stimulation Device and Provides Tailored Relief to Multiple Pain Areas and Adds More Treatment Options for Evolving Pain Conditions